Drug Profile
Research programme: phosphodiesterase III inhibitors - VIVUS
Latest Information Update: 10 Dec 2021
Price :
$50
*
At a glance
- Originator VIVUS
- Class
- Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Erectile dysfunction
Most Recent Events
- 18 Sep 2006 Discontinued - Preclinical for Erectile dysfunction in USA (unspecified route)
- 12 Jan 2001 New profile
- 12 Jan 2001 Preclinical development for Erectile dysfunction in USA (Unknown route)